The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
The Dynamics of Cortical and Hippocampal Atrophy in Alzheimer Disease
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Brain atrophy is a validated marker for identifying the risk of developing AD.
“Brain atrophy is a validated marker for identifying the risk of developing AD [16–19], assisting clinicians in making decisions regarding diagnosis and prognosis [20].”
From Association of APOC1 with cortical atrophy during conversion to Alzheimer’s disease (2025) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 2×
“We processed all MRIs automatically using the FreeSurfer software package developed at the A. A. Martinos Center for Biomedical Imaging at Massachusetts General Hospital.”
Desikan, R. S., Ségonne, F., Fischl, B., Quinn, B. T., Dickerson, B. C., Blacker, D., Buckner, R. L., Dale, A. M., Maguire, R. P., Hyman, B. T., et al. (2006) · NeuroImage · doi:10.1016/j.neuroimage.2006.01.021 · Cited by 13,324
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Fischl, B., Salat, D. H., Busa, E., Albert, M., Dieterich, M., Haselgrove, C., van der Kouwe, A., Killiany, R., Kennedy, D., Klaveness, S., et al. (2002) · Neuron · doi:10.1016/s0896-6273(02)00569-x · Cited by 8,610
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863
Meditation experience is associated with increased cortical thickness
Lazar, S. W., Kerr, C. E., Wasserman, R. H., Gray, J. R., Greve, D. N., Treadway, M. T., McGarvey, M., Quinn, B. T., Dusek, J. A., Benson, H., et al. (2005) · NeuroReport · doi:10.1097/01.wnr.0000186598.66243.19 · Cited by 1,698
Arnold, S. E., Hyman, B. T., Flory, J., Damasio, A. R., & Van Hoesen, G. W. (1991) · Cerebral Cortex · doi:10.1093/cercor/1.1.103 · Cited by 1,380
Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease
Jack, C. R., Petersen, R. C., Xu, Y. C., Waring, S. C., O'Brien, P. C., Tangalos, E. G., Smith, G. E., Ivnik, R. J., & Kokmen, E. (1997) · Neurology · doi:10.1212/wnl.49.3.786 · Cited by 1,128
Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD
Jack, C. R., Shiung, M. M., Gunter, J. L., O’Brien, P. C., Weigand, S. D., Knopman, D. S., Boeve, B. F., Ivnik, R. J., Smith, G. E., Cha, R. H., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000110315.26026.ef · Cited by 827 · cited 1×
“Most prior longitudinal studies have found that brain atrophy progressively accelerates throughout the disease process, although those studies mostly focus on global measures, such as wholebrain or ventricular volume,(3) or on a single anatomical structure, such as the hippocampus.(5,10,12) In this study, we used long…”
Whitwell, J. L., Przybelski, S. A., Weigand, S. D., Knopman, D. S., Boeve, B. F., Petersen, R. C., & Jack, C. R. (2007) · Brain · doi:10.1093/brain/awm112 · Cited by 607
Alzheimer neuropathologic alterations in aged cognitively normal subjects
Davis, D. G., Schmitt, F. A., Wekstein, D. R., & Markesbery, W. R. (1999) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199904000-00008 · Cited by 516
Diagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly People
De Meyer, G. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.179 · Cited by 462
Decreased cerebrospinal fluid Aβ 42 correlates with brain atrophy in cognitively normal elderly
Fagan, A. M., Head, D., Shah, A. R., Marcus, D., Mintun, M., Morris, J. C., & Holtzman, D. M. (2009) · Annals of Neurology · doi:10.1002/ana.21559 · Cited by 327
Flagged first, then by citations
Research works printed but not linked: 31
- [3]Fox NC Freeborough PA Brain atrophy progression measured from registered serial MRI: validation and application to Alzheimer’s disease J Magn Reson Imaging 1997 7 6 1069 1075 9400851
- [4]Fox NC Scahill RI Crum WR Rossor MN Correlation between rates of brain atrophy and cognitive decline in AD Neurology 1999 52 8 1687 1689 10331700
- [6]Jack CR Jr Shiung MM Weigand SD Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI Neurology 2005 65 8 1227 1231 16247049 PMC2753547
- [7]Jack CR Jr Weigand SD Shiung MM Atrophy rates accelerate in amnestic mild cognitive impairment Neurology 2008 70 19 pt 2 1740 1752 18032747 PMC2734477
- [8]Holland D Brewer JB Hagler DJ Fennema-Notestine C Dale AM Alzheimer’s Disease Neuroimaging Initiative Subregional neuroanatomical change as a biomarker for Alzheimer’s disease [published correction appears in Proc Natl Acad Sci U S A. 2010;107(14):6551] Proc Natl Acad Sci U S A 2009 106 49 20954 20959 19996185 PMC2791580
- [10]Fox NC Warrington EK Freeborough PA Presymptomatic hippocampal atrophy in Alzheimer’s disease: a longitudinal MRI study Brain 1996 119 pt 6 2001 2007 9010004
- [11]Scahill RI Schott JM Stevens JM Rossor MN Fox NC Mapping the evolution of regional atrophy in Alzheimer’s disease: unbiased analysis of fluid-registered serial MRI Proc Natl Acad Sci U S A 2002 99 7 4703 4707 11930016 PMC123711
- [12]Schuff N Woerner N Boreta L MRI of hippocampal volume loss in early Alzheimer’s disease in relation to ApoE genotype and biomarkers Brain 2009 132 pt 4 1067 1077 19251758 PMC2668943
- [13]Frisoni G Fox N Jack C Scheltens P Thompson PM The clinical use of structural MRI in Alzheimer disease Nat Rev Nephrol 2010 6 2 67 77 20139996 PMC2938772
- [14]Ridha BH Barnes J Bartlett JW Tracking atrophy progression in familial Alzheimer’s disease: a serial MRI study Lancet Neurol 2006 5 10 828 834 16987729
- [15]Narr KL Toga AW Szeszko P Cortical thinning in cingulate and occipital cortices in first episode schizophrenia Biol Psychiatry 2005 58 1 32 40 15992520
- [16]Shaw P Kabani NJ Lerch JP Neurodevelopmental trajectories of the human cerebral cortex J Neurosci 2008 28 14 3586 3594 18385317 PMC6671079
- [18]Chan D Janssen JC Whitwell JL Change in rates of cerebral atrophy over time in early-onset Alzheimer’s disease: longitudinal MRI study Lancet 2003 362 9390 1121 1122 14550701
- [19]Rusinek H Endo Y De Santi S Atrophy rate in medial temporal lobe during progression of Alzheimer disease Neurology 2004 63 12 2354 2359 15623699
- [20]Sluimer JD van der Flier WM Karas GB Accelerating regional atrophy rates in the progression from normal aging to Alzheimer’s disease Eur Radiol 2009 19 12 2826 2833 19618189 PMC2778773
- [21]Amieva H Jacqmin-Gadda H Orgogozo J-M The 9 year cognitive decline before dementia of the Alzheimer type: a prospective population-based study Brain 2005 128 pt 5 1093 1101 15774508
- [22]Stern Y Liu X Albert M Application of a growth curve approach to modeling the progression of Alzheimer’s disease J Gerontol A Biol Sci Med Sci 1996 51 4 M179 M184 8681001
- [24]Caroli A Frisoni GB Alzheimer’s Disease Neuroimaging Initiative The dynamics of Alzheimer’s disease biomarkers in the Alzheimer’s Disease Neuroimaging Initiative cohort Neurobiol Aging 2010 31 8 1263 1274 20538373 PMC3467365
- [28]Fagan A Roe C Xiong C Mintun M Morris J Holtzman D Cerebrospinal fluid tau/β-amyloid42 ratio as a prediction of cognitive decline in nondemented older adults Arch Neurol 2007 64 3 343 349 17210801
- [30]Petersen RC Mild cognitive impairment as a diagnostic entity J Intern Med 2004 256 3 183 194 15324362
- [31]Fischl B Sereno MI Dale AM Cortical surface-based analysis, II: inflation, flattening, and a surface-based coordinate system Neuroimage 1999 9 2 195 207 9931269
- [32]Fischl B Dale AM Measuring the thickness of the human cerebral cortex from magnetic resonance images Proc Natl Acad Sci U S A 2000 97 20 11050 11055 10984517 PMC27146
- [34]Buckner RL Head D Parker J A unified approach for morphometric and functional data analysis in young, old, and demented adults using automated atlas-based head size normalization: reliability and validation against manual measurement of total intracranial volume Neuroimage 2004 23 2 724 738 15488422
- [35]Marcus DS Wang TH Parker J Csernansky JG Morris JC Buckner RL Open Access Series of Imaging Studies (OASIS): cross-sectional MRI data in young, middle aged, nondemented, and demented older adults J Cogn Neurosci 2007 19 9 1498 1507 17714011
- [36]Fischl B Sereno MI Tootell RBH Dale AM High-resolution intersubject averaging and a coordinate system for the cortical surface Hum Brain Mapp 1999 8 4 272 284 10619420 PMC6873338
- [37]Folstein MF Robins LN Helzer JE The Mini-Mental State Examination Arch Gen Psychiatry 1983 40 7 812 6860082
- [38]Draper NR Smith H Applied Regression Analysis New York John Wiley & Sons 1966
- [39]Dickerson BC Bakkour A Salat DH The cortical signature of Alzheimer’s disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals Cereb Cortex 2009 19 3 497 510 18632739 PMC2638813
- [40]Desikan RS Sabuncu MR Schmansky NJ Alzheimer’s Disease Neuroimaging Initiative. Selective disruption of the cerebral neocortex in Alzheimer’s disease PLoS One 2010 5 9 e12853 10.1371/journal.pone.0012853 20886094 PMC2944799 · DOI
- [41]Becker JA Hedden T Carmasin J Amyloid-β associated cortical thinning in clinically normal elderly [published online November 17, 2010] Ann Neurol 10.1002/ana.22333/full PMC3117980 21437929 · DOI
- [42]Mormino EC Kluth JT Madison CM Alzheimer’s Disease Neuroimaging Initiative Episodic memory loss is related to hippocampal-mediated β-amyloid deposition in elderly subjects Brain 2009 132 pt 5 1310 1323 19042931 PMC2677792
Cited by
Sorted by citations
Fischl, B. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2012.01.021 · Cited by 9,526
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Within-subject template estimation for unbiased longitudinal image analysis
Reuter, M., Schmansky, N. J., Rosas, H. D., & Fischl, B. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2012.02.084 · Cited by 2,356
LaMontagne, P. J., Benzinger, T. L., Morris, J. C., Keefe, S., Hornbeck, R., Xiong, C., Grant, E., Hassenstab, J., Moulder, K., Vlassenko, A. G., et al. (2019) · medRxiv · doi:10.1101/2019.12.13.19014902 · Cited by 779
“In the Trail Making Test participants were asked to make a trail by connecting a series of numbers (1-26) for part A and connecting a series of alternating numbers and letters (1-A-2-B) for part B.”
La Joie, R., Visani, A. V., Baker, S. L., Brown, J. A., Bourakova, V., Cha, J., Chaudhary, K., Edwards, L., Iaccarino, L., Janabi, M., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aau5732 · Cited by 612
Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease
Benzinger, T. L. S., Blazey, T., Jack, C. R., Koeppe, R. A., Su, Y., Xiong, C., Raichle, M. E., Snyder, A. Z., Ances, B. M., Bateman, R. J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1317918110 · Cited by 391
Statistical analysis of longitudinal neuroimage data with Linear Mixed Effects models
Bernal-Rusiel, J. L., Greve, D. N., Reuter, M., Fischl, B., & Sabuncu, M. R. (2013) · NeuroImage · doi:10.1016/j.neuroimage.2012.10.065 · Cited by 360
Self-citationNeuroimaging biomarkers for Alzheimer’s disease.
Márquez, F., & Yassa, M. A. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0325-5 · Cited by 289
Brain injury biomarkers are not dependent on β‐amyloid in normal elderly
Knopman, D. S., Jack, C. R., Wiste, H. J., Weigand, S. D., Vemuri, P., Lowe, V. J., Kantarci, K., Gunter, J. L., Senjem, M. L., Mielke, M. M., et al. (2013) · Annals of Neurology · doi:10.1002/ana.23816 · Cited by 183
Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease
Prestia, A., Caroli, A., van der Flier, W. M., Ossenkoppele, R., Van Berckel, B., Barkhof, F., Teunissen, C. E., Wall, A. E., Carter, S. F., Schöll, M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e3182872830 · Cited by 184
The Role of Cathepsin D in the Pathogenesis of Human Neurodegenerative Disorders
Vidoni, C., Follo, C., Savino, M., Melone, M. A. B., & Isidoro, C. (2016) · Medicinal Research Reviews · doi:10.1002/med.21394 · Cited by 164
Bhagwat, N., Viviano, J. D., Voineskos, A. N., Chakravarty, M. M., & Initiative, A. D. N. (2018) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1006376 · Cited by 157
Mediterranean diet, micronutrients and macronutrients, and MRI measures of cortical thickness
Staubo, S. C., Aakre, J. A., Vemuri, P., Syrjanen, J. A., Mielke, M. M., Geda, Y. E., Kremers, W. K., Machulda, M. M., Knopman, D. S., Petersen, R. C., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.06.2359 · Cited by 147
Shapes of the Trajectories of 5 Major Biomarkers of Alzheimer Disease
Jack, C. R., Vemuri, P., Wiste, H. J., Weigand, S. D., Lesnick, T. G., Lowe, V., Kantarci, K., Bernstein, M. A., Senjem, M. L., Gunter, J. L., et al. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.3405 · Cited by 145
Alzheimer’s disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline
Bucci, M., Chiotis, K., Nordberg, A., & Initiative, F. T. A. D. N. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01263-2 · Cited by 140
Bernal-Rusiel, J. L., Reuter, M., Greve, D. N., Fischl, B., & Sabuncu, M. R. (2013) · NeuroImage · doi:10.1016/j.neuroimage.2013.05.049 · Cited by 125
Self-citationThe implications of different approaches to define AT(N) in Alzheimer disease
Mattsson-Carlgren, N., Leuzy, A., Janelidze, S., Palmqvist, S., Stomrud, E., Strandberg, O., Smith, R., & Hansson, O. (2020) · Neurology · doi:10.1212/wnl.0000000000009485 · Cited by 114
In vivo characterization of the early states of the amyloid-beta network
Sepulcre, J., Sabuncu, M. R., Becker, A., Sperling, R., & Johnson, K. A. (2013) · Brain · doi:10.1093/brain/awt146 · Cited by 117
Self-citationThe dynamics of biomarkers across the clinical spectrum of Alzheimer's disease
Hadjichrysanthou, C., Evans, S., Bajaj, S., Siakallis, L. C., McRae-McKee, K., de Wolf, F., Anderson, R. M., & Initiative, T. A. D. N. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00636-z · Cited by 86
“Hence, such brain regions may be more sensitive biomarkers to changes than bigger brain regions [66].”
Srinivasan, D., Erus, G., Doshi, J., Wolk, D. A., Shou, H., Habes, M., & Davatzikos, C. (2020) · NeuroImage · doi:10.1016/j.neuroimage.2020.117248 · Cited by 45
Schwarz, A. J., Sundell, K. L., Charil, A., Case, M. G., Jaeger, R. K., Scott, D., Bracoud, L., Oh, J., Suhy, J., Pontecorvo, M. J., et al. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.05.007 · Cited by 40
Biomarker-based signature of alzheimer's disease in pre-MCI individuals
Chipi, E., Salvadori, N., Farotti, L., & Parnetti, L. (2019) · Brain Sciences · doi:10.3390/brainsci9090213 · Cited by 27
Association of APOC1 with cortical atrophy during conversion to Alzheimer’s disease
Oh, S., Kim, S., Kim, J. P., Seo, S. W., Park, B.-Y., & Park, H. (2025) · GeroScience · doi:10.1007/s11357-025-01695-6 · Cited by 4
Metadata
- Authors
- Sabuncu, M. R.
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2011-08-01
- Volume
- 68
- Issue
- 8
- Pages
- 1040
- ISSN
- 0003-9942
- PMC
- PMC3248949
- Cited by
- 339
- References
- 15
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
